ArticleCancer cell2024
Interferon-stimulated neutrophils as a predictor of immunotherapy response.
Registry-linked trialOpen access · hybridAbstract read
In one paragraph
Article in Cancer cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07246759 (NEUTROFLOW), which is not on this map. Cited by 109 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed, 2 pooled it
31.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NEUTROFLOW: Development and Validation of a Pan-cancer Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis of Blood Samples
Who cites it
109 citing papers in PubMed, 2 syntheses or guidelines pooled it, 130 citations in OpenAlex.
- Predicting immunotherapy response of advanced bladder cancer through a meta-analysis of six independent cohorts.Nature communications · 2025Pooled it
- Inflammatory markers as prognostic markers in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Pre-existing systemic immune state and dynamic myeloid remodeling shape response to neoadjuvant PD-L1 blockade.Journal for immunotherapy of cancer · 2026Trial
- CCL3+ Neutrophil Signature Predicts Response to Neoadjuvant Toripalimab plus Chemotherapy in Patients with Hypopharyngeal Squamous Cell Carcinoma: A Phase II Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- 4-1BBCell reports. Medicine · 2025Trial
- The safety, tolerability, pharmacokinetics, and pharmacodynamics of nebulized pegylated interferon α-2b in healthy adults: a randomized phase 1 trial.BMC pharmacology & toxicology · 2025Trial
- Novel lipid nanoparticle in a mRNA cancer vaccine drives tumor control via type I IFNs and effector CD8Molecular therapy. Nucleic acids · 2026Article
- Neutrophil-driven immunosuppression in cancer.Cell insight · 2026Review
- Senescent-Like Neutrophils Shape Angiogenic Immunosuppressive Niches in Colorectal Cancer Liver Metastasis.Cancer discovery · 2026Article
- Type I IFN dynamics orchestrate protective ICAM1iScience · 2026Article
- Inhibition of the lipocalin-2-phosphatidylserine axis restores natural killer cell immune surveillance.Cell reports. Medicine · 2026Article
- Leveraging Microphysiological Systems to Facilitate Neutrophil-Based Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- HIF1AJournal for immunotherapy of cancer · 2026Article
- Neutrophils in cancer.Nature reviews. Cancer · 2026Review
- Optimization of Ultrasonic-Assisted Extraction, Structural Characterization, and Bioactivities of Polysaccharides fromAntioxidants (Basel, Switzerland) · 2026Article
- Biophysical reprogramming of immunosuppressive neutrophils by cold atmospheric plasma reinvigorates antitumor immunity.Science advances · 2026Article
- Single-cell profiling of natural killer/T-cell lymphoma reveals stratified immune features and potential therapeutic implications.Nature communications · 2026Article
- Single-cell transcriptomic unveils tumor-mediated reprogramming of neutrophils and their unique vulnerability that inhibits metastasis.Science advances · 2026Article
- The diversity of STING in regulating immune cell function and its role in liver diseases: from bench to bedside.Cell & bioscience · 2026Review
- CD300ld on pathologically activated neutrophils promotes tumor immune suppression by binding phosphatidylserine on CD8Nature cancer · 2026Article
49 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 8 institutions in 3 countries.
Madeleine BenguiguiCell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel; Rappaport Technion Integrated Cancer Center, Technion - Israel Institute of Technology, Haifa, Israel.
Tim J CooperCell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel; Rappaport Technion Integrated Cancer Center, Technion - Israel Institute of Technology, Haifa, Israel; Department of Immunology, Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel. Electronic address: timcooper@technion.ac.il.
Prajakta KalkarDepartment of Human Biology, the Faculty of Natural Sciences, University of Haifa, Haifa, Israel.
Sagie Schif-ZuckDepartment of Human Biology, the Faculty of Natural Sciences, University of Haifa, Haifa, Israel.
Ruth HalabanDepartment of Dermatology, Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA.
Antonella BacchiocchiDepartment of Dermatology, Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA.
Iris KamerInstitute of Oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Abhilash DeoCell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel; Rappaport Technion Integrated Cancer Center, Technion - Israel Institute of Technology, Haifa, Israel.
Bar ManoblaCell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel; Rappaport Technion Integrated Cancer Center, Technion - Israel Institute of Technology, Haifa, Israel.
Rotem MenachemCell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel; Rappaport Technion Integrated Cancer Center, Technion - Israel Institute of Technology, Haifa, Israel.
Jozafina Haj-ShomalyCell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel; Rappaport Technion Integrated Cancer Center, Technion - Israel Institute of Technology, Haifa, Israel.
Avital VorontsovaCell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel; Rappaport Technion Integrated Cancer Center, Technion - Israel Institute of Technology, Haifa, Israel.
Ziv RavivCell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel; Rappaport Technion Integrated Cancer Center, Technion - Israel Institute of Technology, Haifa, Israel.
Chen BuxbaumCell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel; Rappaport Technion Integrated Cancer Center, Technion - Israel Institute of Technology, Haifa, Israel.
Petros ChristopoulosDepartment of Thoracic Oncology, Thoraxklinik and National Center for Tumor Diseases (NCT) at Heidelberg University Hospital, 69126 Heidelberg, Germany; Translational Lung Research Center Heidelberg, Member of the German Center for Lung Research (DZL), Heidelberg, Germany.
Jair BarInstitute of Oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Michal LotemDepartment of Melanoma and Cancer Immunotherapy, Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Mario SznolDepartment of Medicine, Division of Medical Oncology, Yale University School of Medicine, New Haven, CT, USA.
Amiram ArielDepartment of Human Biology, the Faculty of Natural Sciences, University of Haifa, Haifa, Israel.
Shai S Shen-OrrRappaport Technion Integrated Cancer Center, Technion - Israel Institute of Technology, Haifa, Israel; Department of Immunology, Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
Yuval ShakedCell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel; Rappaport Technion Integrated Cancer Center, Technion - Israel Institute of Technology, Haifa, Israel. Electronic address: yshaked@technion.ac.il.
Technion – Israel Institute of Technology · ILUniversity of Haifa · ILYale Cancer Center · USHadassah Medical Center · ILHeidelberg University · DESheba Medical Center · ILTel Aviv University · ILYale University · US
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MYale SPORE in Skin CancerP50CA121974 · NCI · YALE UNIVERSITY · PI MARCUS W BOSENBERG, Harriet M. Kluger · 2006 to 2026
$43.9MThe effects of immune-age on immune-response and the molecular mechanisms which drive itP01AI153559 · NIAID · STANFORD UNIVERSITY · PI DAVIS, MARK MORRIS · 2021 to 2025
$17.8M(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapyR01CA231325 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CURIEL, TYLER J., SHEN-ORR, SHAI SHLOMO · 2018 to 2022
$3.1MNCATS NIH HHS UL1 TR001863NCI NIH HHS P50 CA121974NCI NIH HHS R01 CA231325NIAID NIH HHS P01 AI153559
Abstract
Despite the remarkable success of anti-cancer immunotherapy, its effectiveness remains confined to a subset of patients-emphasizing the importance of predictive biomarkers in clinical decision-making and further mechanistic understanding of treatment response. Current biomarkers, however, lack the power required to accurately stratify patients. Here, we identify interferon-stimulated, Ly6E
Indexed as
Carcinoma, Non-Small-Cell LungLung NeoplasmsAnimalsBiomarkersHumansImmunotherapyInterferonsMiceNeutrophilsBiomarkersInterferonsBiomarkerimmunotherapyinterferonmelanomaneutrophilsnon-small cell lung cancerresponseSTING
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT07246759ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.